| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 93,803 | 93,550 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -3,866 | 10,990 |
| Cash and cash equivalents at beginning of period | 39,079 | - |
| Cash and cash equivalents at end of period | 35,213 | - |
CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. (CTMX)